Pure Global

Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin - Trial NCT04648696

Access comprehensive clinical trial information for NCT04648696 through Pure Global AI's free database. This Phase 4 trial is sponsored by Wake Forest University Health Sciences and is currently Recruiting. The study focuses on Infection. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04648696
Phase 4
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT04648696
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin in Outpatient Parenteral Antibiotic Therapy: a Prospective, Randomized Trial

Study Focus

Infection

Vancomycin CI

Interventional

drug

Sponsor & Location

Wake Forest University Health Sciences

Winston-Salem, United States of America

Timeline & Enrollment

Phase 4

Mar 03, 2021

Oct 01, 2022

200 participants

Primary Outcome

Incidence of Nephrotoxicity

Summary

Evaluate the safety and outcomes associated between the two treatment modalities

ICD-10 Classifications

Bacterial infection, unspecified
Bacterial, viral and other infectious agents
Infection following immunization
Other infectious diseases
Viral infection, unspecified

Data Source

ClinicalTrials.gov

NCT04648696

Non-Device Trial